Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy
Ishihara, Hiroki, Kondo, Tsunenori, Yoshida, Kazuhiko, Omae, Kenji, Takagi, Toshio, Iizuka, Junpei, Tanabe, KazunariLanguage:
english
Journal:
Urologic Oncology: Seminars and Original Investigations
DOI:
10.1016/j.urolonc.2017.05.014
Date:
June, 2017
File:
PDF, 981 KB
english, 2017